Arvinas (ARVN) and Pfizer (PFE) on Tuesday reported "encouraging" preliminary data from an ongoing phase 1b trial of their vepdegestrant drug candidate in combination with Eli Lilly's (LLY) abemaciclib kinase inhibitor in patients with a form of breast cancer.
Trial results from 16 patients with locally advanced or metastatic estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer demonstrated a tolerable safety profile for the combination of 200 milligrams of vepdegestrant daily with 150 milligrams of abemaciclib twice daily.
The drug combination showed a clinical benefit rate of 62.5% and an overall response rate of 26.7% among breast cancer patients previously treated with a CDK4/6 inhibitor, the companies said.
Arvinas shares were down more than 2% in recent trading, while Pfizer was off by about 1%.
Price: 25.00, Change: -0.08, Percent Change: -0.34
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。